Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer
Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer
复制标题
DOI：
10.1111/igc.0b013e3181c10513
复制
发表时间：
2009-12-01
影响因子：
4.8
通讯作者：
Marsh, Sharon
中科院分区：
文献类型：
--
作者：
Marsh, Sharon
目的：紫杉醇（紫杉醇或多西他赛）和铂类（顺铂或卡铂）化疗是治疗卵巢癌的常用方案。尽管最初对治疗有很高的反应，但5年生存率仍然很低。药物基因组学标记物的鉴定，以确定患者不太可能响应或严重毒性的风险将有助于个性化卵巢癌treatment.Materials and Methods的目标：大多数研究已经评估了单核苷酸多态性的基因参与药物的药代动力学和药效学的药物。变异的其他机制，包括基因表达和拷贝数变异的表观遗传控制，可能发挥重要作用。此外，非遗传因素（如合并用药）以及生理和环境因素也可能影响个体对紫杉烷和铂类药物治疗的反应。
Objectives: Taxane (paclitaxel or docetaxel) and platinum (cisplatin or carboplatin) chemotherapy is commonly used in the treatment of ovarian cancer. Despite an initial high response to therapy, the 5-year Survival rate remains low. The identification of pharmacogenomic markers to identify patients unlikely to respond or at risk for severe toxicity will assist in the goal of individualizing ovarian cancer treatment.Materials and Methods: Most Studies have assessed single nucleotide polymorphisms from genes involved in the pharmacokinetics and pharmacodynamics of the drugs.Results: Unfortunately, most markers identified have not been replicated in subsequent studies.Conclusions: Other mechanisms of variability, including epigenetic control of gene expression and copy number variation, may play important roles. In addition, nongenetic influences Such as Concurrent medications, and physiological and environmental factors could also affect individual responses to taxane and platinum therapy.